Everything drug pricing and policy, every day
Interrupting your Friday with a quick flag of another decision in an IRA case
And a new paper outlines what a more formal cost-effectiveness review process might look like under the IRA
And it’s worth noting the hat trick that Arnold Ventures scored last week in JAMA
And the PBM industry is crowing about the need to drive down drug prices, raising the question: Are PBM-owned drug companies dropping prices?
And one of the bigger pharma-related implications of the tax/Medicaid bill is coming into focus
Early reactions to the 340B rebate model announcement suggest we’re about to take a step onto a slippery slope
And unveiling “On Some Tropical Shore,” the jingle to accompany references to the Jimmy 340Buffett Rule
And pharma execs are taking the latest tariff news in stride
And all sides agree: Importing foreign price controls via ‘most favored nation’ is a terrible way to handle drug prices
